ZTS

NYSE

Zoetis Inc.

Health Care, Pharmaceuticals

$72.66

close 7 Aug 2026

-51.24%

52-week change

$30.09B

market cap

$71.47

$160.48

52-week range

Valuation

Market cap$30.09B

P/E (TTM / 5y avg)11.87x33.61x

Forward P/E (FY2026 / FY2027)11.25x10.28x

PEG (TTM / fwd)1.161.20

P/S (TTM)3.16x

P/B9.56x

EV/EBITDA (TTM)9.37x

FCF yield (TTM)7.70%

Cash flow & dividend

FCF (TTM)$2.32B

FCF per share (TTM)$5.59

FCF margin (TTM)24.31%

Dividend yield (indicated / 5y avg)2.92%1.08%

Annualized dividend$2.12

Payout ratio (EPS / FCF)33.71%38.39%

Growth & quality

Revenue YoY, latest Q-0.24%

Diluted EPS YoY, latest Q+1.23%

Operating margin (TTM)—

Net margin (TTM)27.69%

ROE (latest FY)80.25%

Net debt / EBITDA (TTM)1.88

Interest coverage (TTM)—

Price

-63.94%-18.51%/yrover 5y

Weekly closes · split-adjusted

close 7 Aug 2026

Fundamentals

Fiscal years, last 10, CAGR chips on growth series, plus a dimmed trailing-twelve-month bar

Revenue

5Y CAGR +7.24%10Y CAGR +7.11%

Diluted EPS

5Y CAGR +11.97%10Y CAGR +24.37%

FCF per share

5Y CAGR +8.04%10Y CAGR +19.27%

Operating cash flow

5Y CAGR +6.44%10Y CAGR +15.90%

Free cash flow

5Y CAGR +6.41%10Y CAGR +17.90%

Dividends per share

5Y CAGR +20.34%10Y CAGR +19.51%

Payout ratio

FCF payout ratio

FCF margin

Return on equity

Shares outstanding

5Y CAGR -2.22%10Y CAGR -1.56%

Net debt / EBITDA

Earnings

Street estimates, not SEC filings

Next / Q3 FY26

Date2 Nov 2026bmo

EPS estimate$1.87

Revenue estimate$2.53B

Last reported

Date—

EPS——

Revenue——